Scinai Immunotherapeutics Aktie

0,4600 EUR -0,0080 EUR -1,71 %

15:25:02

FSE

0,5478 USD -0,0293 USD -5,08 %

15:45:43

BTT

Scinai Immunotherapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Div. Rendite0,00%

WKNA40DEH

ISINUS09073Q3039

SymbolSCNI

Scinai Immunotherapeutics Aktien News

Sortieren:Datum Meistgelesen

07.01.26PR NewswireScinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

02.12.25PR NewswireScinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

06.10.25PR NewswireScinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

WerbungScinai Immunotherapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

02.09.25PR NewswireScinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

29.07.25PR NewswireScinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

26.06.25PR NewswireScinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"

12.06.25PR NewswireScinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

05.06.25PR NewswireScinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

30.05.25PR NewswireScinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

07.05.25PR NewswireScinai Announces Annual Financial Results for 2024

01.05.25PR NewswireScinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

27.03.25PR NewswireScinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

17.03.25PR NewswireScinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

05.03.25PR NewswireSCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

06.01.25PR NewswireScinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

16.12.24PR NewswireScinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

05.12.24PR NewswireProf. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

27.11.24PR NewswireDr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

22.11.24PR NewswireScinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

31.10.24PR NewswireScinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

16.09.24PR NewswireScinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

29.08.24PR NewswireScinai Regains Full Compliance with Nasdaq Listing Requirements

21.08.24PR NewswireScinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

20.08.24PR NewswireScinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

15.08.24PR NewswireScinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

13.08.24PR NewswireScinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

23.07.24PR NewswireScinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

15.07.24PR NewswireScinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

08.07.24PR NewswireScinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

03.07.24PR NewswireScinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

02.07.24PR NewswireScinai Publishes Q1 2024 Financial Results and Provides Business Update

13.06.24PR NewswireScinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Scinai Immunotherapeutics News

Scinai Immunotherapeutics News: auf dieser Seite finden Sie alle Scinai Immunotherapeutics News und Nachrichten zur Scinai Immunotherapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Scinai Immunotherapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Scinai Immunotherapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.